News 2024-05-16
Porton at CPhI North America again
We've had an exciting few days at CPhI North America. We want to express our sincere gratitude to all the present and potential future partners we've engaged with. Whether you require assistance with API route scouting, chemistry optimization, or the manufacturing of intermediates, RSM, or finished API, our teams are ready to support you from our locations in Cranbury (NJ), Slovenia, or our sites in China.
If you are focused on drug product development, the Porton team is equipped to aid in the development of tablets, capsules, liquids, or sterile products, starting from pre-formulation and DS-DP coprocessing through to GMP manufacturing, including high-potent product capabilities. Additionally, our global reach extends to the development of topical and transdermal patch products. How can Porton help you? Contact us.
|
Small Molecules CDMO |
TIDES CDMO |
Biologics (Antibody & ADCs) CDMO |
|
|
|
Others
More
News 2025-04-16
Porton Advanced's End-to-End CDMO Solutions Accelerates IND Approval of Tasly's Innovative Dual-Targeting CAR-T Therapy
April 12, 2025 - Porton Advanced proudly announces its CDMO support for TASLY PHARMACEUTICAL CO., LTD’s Innovative Dual-Targeting CAR-T Therapy, "P134 Cell Injection," which has received Investigational New Drug (IND) approval from China's National Medical Products Administration (NMPA) (Approval No.: 2025LP01030). This breakthrough CAR-T therapy is indicated for recurrent glioblastoma (GBM).
News 2025-04-11
Porton Newsletter - Q1 2025 Recap
Technical Enabling Services & Solutions Company Events ESG Marketing Activities
